Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Scientists find new way to make beating heart cells from body's own cells

Scientists at the Gladstone Institute of Cardiovascular Disease have found a new way to make beating heart cells from the body's own cells that could help regenerate damaged hearts. Over 5 million Americans suffer from heart failure because the heart has virtually no ability to repair itself after a heart attack.

6 Aug 2010

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Citing research that demonstrates the cost savings and health benefits of providing Diabetes Self-Management Training (DSMT) to patients with pre-diabetes, the American Association of Diabetes Educators today called on private insurers and Medicare to include education as a covered benefit for this population.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

The true power of genomic research lies in its ability to help scientists understand biological processes, particularly those that - when altered - can lead to disease. This power is demonstrated dramatically in a pair of papers published today in the journal Nature. In the first, a global team of researchers describes 95 different variations across the genome that contribute in different degrees to alterations in blood cholesterol and triglyceride levels in multiple human populations. In the second report, close examination of just one of these common variants not only reveals the involvement of an unexpected genetic pathway in lipid metabolism but also provides a blueprint for using genomic findings to unravel biological connections between lipid levels and coronary heart disease.

5 Aug 2010

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

Cardiogenesis Corporation, a leading developer of surgical products used to treat cardiac patients suffering from severe angina, today reported financial results for its second quarter and first half ended June 30, 2010.

5 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Celera decreases second-quarter net loss to $6.1 million

Celera Corporation today reported net revenues of $32.6 million for the second quarter of 2010 that ended June 26, 2010, compared to $41.4 million for the prior year quarter. For the second quarter of 2010, Celera reported a net loss of $6.1 million, or $0.07 per share, compared to a net loss of $31.7 million, or $0.39 per share, for the prior year quarter.

4 Aug 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

Diffusion Pharmaceuticals receives patent for drug formulation

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes drug formulation and use claims relating to Diffusion's entire family of first-in-class new chemical entities. Diffusion Pharmaceuticals is commercializing this family of first-in-class drug candidates to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level.

3 Aug 2010

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body.

3 Aug 2010

FDA approves N30 Pharma's NDA for N6022 GSNOR

N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).

3 Aug 2010

Healthy heart may slow down aging of brain: Study

Keep your heart healthy and you may slow down the aging of your brain, according to a new study reported in Circulation: Journal of the American Heart Association.In the study, people whose hearts pumped less blood had brains that appeared older than the brains of those whose hearts pumped more blood. Decreased cardiac index, the amount of blood that pumps from the heart in relation to a person's body size, was associated with decreased brain volume using magnetic resonance imaging (MRI).

3 Aug 2010

Vanguard signs definitive agreement to acquire Arizona Heart Institute

Vanguard Health Systems and Arizona Heart Institute (AHI) announced today that they have signed a definitive agreement for Vanguard to acquire Arizona Heart Institute, one of the world's leading providers of cardiovascular care. Through this agreement, AHI will align with Abrazo Health Care, a Phoenix-based subsidiary of Vanguard, to become part of its distributive cardiovascular network of community-based physicians, providing future opportunities to greatly expand cardiovascular services and patient base throughout the region.

3 Aug 2010

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

A new UCLA study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status.

2 Aug 2010

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, today announced that it has achieved positive safety and tolerability results in the first clinical study of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure. Each year in the United States, more than one million patients are hospitalized with acute heart failure.

2 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Scientists find new way to make beating heart cells from body's own cells

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Genzyme, Isis announce results of two mipomersen phase 3 studies

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

FDA designates XOMA 052 orphan drug for Behcet's disease

Celera decreases second-quarter net loss to $6.1 million

POZEN reports $16.2M net income for second-quarter 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

Diffusion Pharmaceuticals receives patent for drug formulation

miRagen Therapeutics develop MicroRNA based therapeutics for cardiovascular and muscle disease

FDA approves N30 Pharma's NDA for N6022 GSNOR

Healthy heart may slow down aging of brain: Study

Vanguard signs definitive agreement to acquire Arizona Heart Institute

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in